The market is overly focused on competitive threats to Legend Biotech, causing it to miss the company's fundamental strength. Its drug Carvicti achieved $1.9B in 2025 sales and is projected to grow 50% in 2026. With profitability expected this year and an unpriced pipeline, the stock appears poised for growth despite negative sentiment.
Iovance is viewed as a top idea because investors previously misunderstood its core opportunity. The negative sentiment ignored the growth outlook in second-line melanoma, improving margins, and the significant upside from a potential non-small cell lung cancer approval in 2027—a much larger market. This reassessment is driving the stock's recent momentum.
Turns' drug, Turn 701, shows a significant valuation disconnect. Despite demonstrating molecular responses three times better than Novartis's Symblix—a drug with a $4B+ peak sales forecast—Turns' market cap is only 1.2 times that peak sales figure. This superior efficacy in a tough-to-treat population suggests considerable remaining upside for the stock.
To be considered a success, Abivax's oral drug Obifazomad must demonstrate placebo-adjusted long-term remission rates of 25-30% in upcoming data, matching the efficacy of top biologic treatments for ulcerative colitis. Its strong phase two results, showing a 48% rate, suggest this benchmark is achievable, positioning it as a potential "holy grail" oral therapy.